NASDAQ$CLLS
Cellectis SA-ADR · Q1 2025 earnings
Q1 2025 earnings · · Investor relations
Briefing
Cellectis SA reported narrowed net loss in Q4 2024 with continued investment in trait development and strategic cost-saving initiatives.
Cellectis (Cibus) achieved revenue growth in Q4 2024 while significantly reducing net loss compared to the prior year. Operational focus included commercialization progress, expanded strategic collaborations, and cost-cutting measures to extend cash runway.
- Revenue for Q4 2024 was $1,212,000, up from $1,103,000 in Q4 2023
- Net loss decreased significantly to $25,804,000 from $277,208,000
- Cash and cash equivalents stood at $14,433,000 at year-end, before January 2025 offering
- Operating expenses dropped with no goodwill impairment charges this quarter
Headline financials
Revenue & EPS history
Cellectis SA · Revenue · Quarterly
$1.21M
Forward guidance
Cellectis (Cibus) aims to progress its commercial and regulatory efforts in gene editing and sustainable ingredients through 2025 while pursuing strategic alternatives.
Tailwinds
- Filed field research proposal for gene-edited rice in California
- Advanced regulatory support for gene editing in the EU
- Achieved strategic partnerships for rice and canola trait commercialization
- Announced breakthrough edits in soybean HT2 platform
- Secured $22.6 million gross from January 2025 offering
Headwinds
- Continued operating losses driven by R&D and SG&A expenses
- Ongoing royalty liability interest expense of $8.2 million
- Cash runway limited to late Q3 2025 without further financing
- Net loss remained high despite goodwill impairment absence
- High dependency on successful commercialization to generate revenue
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
-2.2%
Avg return
Earnings day
-2.0%
Avg return
5 days after
-0.9%
Avg return
30 days after
38%
16 / 42 earnings
Positive
+9.3%
Q1 2022
Best reaction
-16.4%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +2.7% | +0.3% | -17.6% | |
| Q2 2025 | -16.1% | -13.9% | -12.9% | |
| Q1 2025 | +2.4% | +0.0% | -9.5% | |
| Q4 2024 | -3.9% | +1.6% | +11.6% | |
| Q3 2024 | -1.1% | -1.7% | +5.0% | |
| Q2 2024 | +1.0% | +2.0% | +11.3% | |
| Q1 2024 | -3.5% | -3.9% | -34.0% | |
| Q3 2023 | -16.4% | -12.2% | +0.7% | |
| Q2 2023 | -3.6% | -3.6% | +4.7% | |
| Q1 2023 | +2.2% | -1.6% | +7.0% | |
| Q4 2022 | -3.9% | -4.5% | -4.2% | |
| Q3 2022 | -7.5% | -9.5% | -13.8% | |
| Q2 2022 | +4.2% | +0.6% | +2.1% | |
| Q1 2022 | +9.3% | +20.0% | -2.4% | |
| Q4 2021 | -14.9% | -11.6% | +16.9% | |
| Q3 2021 | -4.8% | -12.7% | -35.8% | |
| Q2 2021 | +7.1% | +5.3% | +14.3% | |
| Q1 2021 | -3.8% | -6.3% | -14.2% | |
| Q4 2020 | -9.7% | +7.5% | -2.0% | |
| Q3 2020 | +3.4% | +2.9% | +78.4% | |
| Q2 2020 | -2.0% | +1.4% | -5.6% | |
| Q1 2020 | +2.7% | +7.2% | +15.3% | |
| Q4 2019 | +0.3% | -22.8% | -46.9% | |
| Q3 2019 | +2.8% | +9.3% | +18.2% | |
| Q2 2019 | -1.8% | +0.8% | -5.4% | |
| Q1 2019 | -3.2% | -6.7% | -26.5% | |
| Q4 2018 | +3.7% | +7.0% | +9.0% | |
| Q3 2018 | -5.4% | -14.7% | -26.6% | |
| Q2 2018 | +0.0% | -1.2% | +2.0% | |
| Q1 2018 | -1.1% | -2.9% | +6.6% | |
| Q4 2017 | -7.1% | -1.2% | -11.2% | |
| Q3 2017 | -6.4% | -5.3% | +6.9% | |
| Q2 2017 | -2.3% | -1.9% | +36.0% | |
| Q1 2017 | +1.2% | +2.4% | +0.6% | |
| Q4 2016 | -4.1% | +2.5% | +6.7% | |
| Q3 2016 | -3.3% | +0.3% | -5.3% | |
| Q2 2016 | -3.0% | -5.2% | -13.0% | |
| Q1 2016 | -7.6% | — | — | |
| Q4 2015 | +2.5% | — | — | |
| Q3 2015 | -0.9% | — | — | |
| Q2 2015 | +0.9% | — | — | |
| Q1 2015 | -1.6% | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q4 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro